

Acalabrutinib

In combination with bendamustine and rituximab for previously untreated mantle cell lymphoma

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended acalabrutinib in combination with bendamustine and rituximab for inclusion on the MOH List of Subsidised Drugs for previously untreated mantle cell lymphoma. The decision was based on the uncertain extent of clinical benefit, unacceptable pricing and price-volume arrangement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim eligibility for acalabrutinib are provided in the Annex.

ANNEX

Recommendations by the MOH Drug Advisory Committee

Drug preparation	Company-proposed clinical indication	Subsidy class	Eligible for MediShield Life claims
Acalabrutinib 100 mg film-coated tablet	Treatment of patients with previously untreated mantle cell lymphoma.	Not recommended for subsidy	No

 Agency for Care Effectiveness - ACE
  Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at <https://www.ace-hta.gov.sg/about-us/>

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore
 Email: ACE@moh.gov.sg

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.